


1636




**FULBRIGHT & JAWORSKI L.L.P.**  
A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

SHIGHLANDER@FULBRIGHT.COM  
PARTNER  
DIRECT DIAL: (512) 536-3184

TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

April 15, 2004

<b>CERTIFICATE OF MAILING</b> 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
<u>April 15, 2004</u> Date	 Steven L. Highlander

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Re: Serial Number 09/612,809 entitled "THERAPEUTICS AND DIAGNOSTICS FOR CONGENITAL HEART DISEASE BASED ON A NOVEL HUMAN TRANSCRIPTION FACTOR" by Val C. Sheffield  
Our ref: IOWA:042USD1

Commissioner:

Enclosed for filing in the above-referenced patent application is:

1. Resubmitted Amendment and Request for Reconsideration Under 37 C.F.R. §1.111;
2. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/IOWA:042USD1/SLH.

Very truly yours,  
  
 Steven L. Highlander

SLH/cpj

Encl: As noted


25405742.1



CERTIFICATE OF MAILING  
37 C.F.R. §1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450; Alexandria, VA 22313-01450, on the date below:

April 15, 2004  
Date

  
Steven L. Highlander

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Val. C. SHEFFIELD *et al.*

Serial No.: 09/612,809

Filed: July 10, 2000

For: THERAPEUTICS AND DIAGNOSTICS  
FOR CONGENITAL HEART DISEASE  
BASED ON A NOVEL HUMAN  
TRANSCRIPTION FACTOR

Group Art Unit: 1636

Examiner: LEFFERS, G.

Atty. Dkt. No.: IOWA:042USD1/SLH

**RESUBMITTED AMENDMENT AND REQUEST FOR  
RECONSIDERATION UNDER 37 C.F.R. §1.111**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-01450

Dear Sir:

This paper is submitted in response to the Office Communication dated March 23, 2004, to which a response is due on April 23, 2004. It is believed that no fees are due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/IOWA:042USD1/SLH.

**Amendments start on page 2 of this response.**

**Remarks start on page 5 of this response.**